Aleksandra A. Pirozhnikova , Maksim V. Stetsyuk , Kseniya A. Kudrevich , Emine E. Abdurakhmanova , Amina I. Umerova , Edgar G. Tamasyan , Dilyara Yu. Kovali , Koryun A. Tovmasyan , Veronika A. Filipova , Aliya A. Diarova , Olga V. Nemirova , Askina A. Bagdasaryan , Khozh-Akhmed A. Shadiev
Abstract
Introduction. Old age is a significant risk factor for all types of skin cancer. Non-melanoma skin cancer (NSCLC) is the most commonly diagnosed type of cancer worldwide and especially affects the elderly. In 2019, in the Russian Federation, NSCLC accounted for 10.6% of the total number of oncological diseases in men and 15.2% in women. During the same period, there was an increase in the incidence: by 7.9% in men and by 17.9% in women. The average age of patients with this disease was 69.7 years.
Aim. to analyze the literature on the prevalence of NSCLC among the elderly, the unique problems faced by patients, as well as recent advances in treatment.
Materials and methods. Research papers were searched in the databases eLibrary, PubMed and Google Scholar until September 2024. The selection of publications was carried out according to the recommendations of PRISMA. 78 studies were included in the review.
Results. The review highlights the importance of adapted approaches to the treatment of NSCLC in the elderly. Given the increasing prevalence of NSCLC in older people, meeting their special needs and concerns is of paramount importance. Ongoing research in this area can improve treatment outcomes and improve the quality of life of elderly patients with NSCLC. The future of geriatric dermatology is likely to depend on these advances providing a more complete understanding of treatments for NSCLC in the elderly.
Conclusion. As the field of dermatology continues to evolve, an individual approach to the treatment of NSCLC in the elderly will be crucial. Active collaboration between healthcare professionals, patients and their families is essential for making informed treatment decisions. Further research is needed to clarify the recommendations and treatment strategies for older people, with a particular focus on optimizing therapeutic outcomes while minimizing the physical, emotional and social impact of NSCLC and its treatment.
Keywords: non-melanoma skin cancer, squamous cell skin cancer, basal cell skin cancer, elderly, treatment, diagnosis, skin.
Aim. to analyze the literature on the prevalence of NSCLC among the elderly, the unique problems faced by patients, as well as recent advances in treatment.
Materials and methods. Research papers were searched in the databases eLibrary, PubMed and Google Scholar until September 2024. The selection of publications was carried out according to the recommendations of PRISMA. 78 studies were included in the review.
Results. The review highlights the importance of adapted approaches to the treatment of NSCLC in the elderly. Given the increasing prevalence of NSCLC in older people, meeting their special needs and concerns is of paramount importance. Ongoing research in this area can improve treatment outcomes and improve the quality of life of elderly patients with NSCLC. The future of geriatric dermatology is likely to depend on these advances providing a more complete understanding of treatments for NSCLC in the elderly.
Conclusion. As the field of dermatology continues to evolve, an individual approach to the treatment of NSCLC in the elderly will be crucial. Active collaboration between healthcare professionals, patients and their families is essential for making informed treatment decisions. Further research is needed to clarify the recommendations and treatment strategies for older people, with a particular focus on optimizing therapeutic outcomes while minimizing the physical, emotional and social impact of NSCLC and its treatment.
Keywords: non-melanoma skin cancer, squamous cell skin cancer, basal cell skin cancer, elderly, treatment, diagnosis, skin.
About the Author
Aleksandra A. Pirozhnikova 1 , Maksim V. Stetsyuk 2 , Kseniya A. Kudrevich 2 , Emine E. Abdurakhmanova 2 , Amina I. Umerova 2 , Edgar G. Tamasyan 2 , Dilyara Yu. Kovali 2 , Koryun A. Tovmasyan 2 , Veronika A. Filipova 3 , Aliya A. Diarova 3 , Olga V. Nemirova 4 , Askina A. Bagdasaryan 5 , Khozh-Akhmed A. Shadiev 61 Mechnikov North-Western State Medical University, Saint Petersburg, Russia
2 Georgievsky Order of the Red Banner Medical Institute, Simferopol, Russia
3 Bashkir State Medical University, Ufa, Russia
4 Moscow University of Humanities and Economics, Moscow, Russia
5 Rostov State Medical University, Rostov-on-Don, Russia
6 Astrakhan State Medical University, Astrakhan, Russia
References
1. Кубанов А.А., Кондрахина И.Н., Плахова К.И., Сайтбурханов Р.Р. Современное представление о патогенезе базальноклеточного рака кожи. Вестник дерматологии и венерологии. 2021;97(5):38-51.
Kubanov A.A., Kondrakhina I.N., Plakhova X.I., Saytburkhanov R.R. Modern understanding of the pathogenesis of basal cell skin cancer. Vestnik Dermatologii i Venerologii. 2021;97(5):38-51 DOI: 10.25208/ vdv1277 (in Russian).
2. Sordi E, Piscitelli P, Albanese C et al. Incidence of Non-Melanoma Skin Cancers in Salento (Southern Italy): A 15-Year Retrospective Analysis from the Cancer Registry of Lecce. Epidemiologia (Basel) 2023;5(1):1-10. DOI: 10.3390/epidemiologia5010001
3. Albert A, Knoll MA, Conti JA, Zbar RIS. Non-Melanoma Skin Cancers in the Older Patient. Curr Oncol Rep 2019 ;21(9):79. DOI: 10.1007/s11912-019-0828-9
4. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). М., 2020.
Kaprin A.D., Starinsky V.V., Shakhzadova A.O. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow, 2020 (in Russian).
5. Apalla Z, Nashan D, Weller RB, Castellsagué X. Skin Cancer: Epidemiology, Disease Burden, Pathophysiology, Diagnosis, and Therapeutic Approaches. Dermatol Ther (Heidelb) 2017;7(Suppl 1):5-19. DOI: 10.1007/s13555-016-0165-y
6. Leiter U, Keim U, Garbe C. Epidemiology of Skin Cancer: Update 2019. Adv Exp Med Biol 2020;1268:123-39. DOI: 10.1007/978-3-030-46227-7_6
7. McFerran E, Donaldson S, Dolan O, Lawler M. Skin in the game: The cost consequences of skin cancer diagnosis, treatment and care in Northern Ireland. J Cancer Policy 2024;39:100468. DOI: 10.1016/j.jcpo. 2024.100468
8. Sinikumpu SP, Jokelainen J, Keinänen-Kiukaanniemi S, Huilaja L. Skin cancers and their risk factors in older persons: a population-based study. BMC Geriatr 2022;22(1):269. DOI: 10.1186/s12877-022-02964-1
9. Рыбкина В.Л., Азизова Т.В., Адамова Г.В. Факторы риска развития злокачественных новообразований кожи. Клиническая дерматология и венерология. 2019;18(5):548-55. DOI: 10.17116/klinderma201918051548
Rybkina V.L., Azizova T.V., Adamova G.V. Risk factors of malignant neoplasms of the skin. Russian Journal of Clinical Dermatology and Venereology. 2019;18(5):548-55. DOI: 10.17116/klinderma2019 18051548 (in Russian).
10. Wendt A, Möhner M. Occupational solar exposure and basal cell carcinoma. A review of the epidemiologic literature with meta-analysis focusing on particular methodological aspects. Eur J Epidemiol 2024 Jan;39(1):13-25. DOI: 10.1007/s10654-023-01061-w
11. Зорина А.И., Зорин В.Л., Копнин П.Б. и др. Старение кожи, ассоциированное с инволюционными изменениями фибробластического дифферона и внеклеточного матрикса дермы. Клиническая дерматология и венерология. 2023;22(3):338-45. DOI: 10.17116/ klinderma202322031338
Zorina A.I., Zorin V.L., Kopnin P.B. et al. Skin aging associated with involutional changes in fibroblastic differon and extracellular matrix of the dermis. Russian Journal of Clinical Dermatology and Venereology. 2023;22(3):338-45. DOI: 10.17116/klinderma202322031338 (in Russian).
12. Перлин Д.В., Александров И.В., Перлина А.Д. и др. Злокачественные новообразования кожи у пациентов после трансплантации почки. Вестник урологии. 2022;10(3):36-43. DOI: 10.21886/2308-6424-2022-10-3-36-43
Perlin D.V., Alexandrov I.V., Perlina A.D., Shmanev A.O., Dymkov I.N. Malignant skin neoplasms in patients after kidney transplantation. Urology Herald. 2022;10(3):36-43. DOI: 10.21886/2308-6424-2022-10-3-36-43 (in Russian).
13. Владимирова Л.Ю., Алькина А.К. Карцинома Меркеля. Современные возможности лекарственной терапии. Злокачественные опухоли. 2023;13(3s1):49-52. DOI: 10.18027/2224-5057-2023-13-3s1-49-52
Vladimirova L.Yu., Alkina A.K. Merkel’s carcinoma. Modern possibilities of drug therapy. Malignant tumours. 2023;13(3s1):49-52. DOI: 10.18027/2224-5057-2023-13-3s1-49-52 (in Russian).
14. Щава С.Н., Сердюкова Е.А., Редькина Н.А. и др. Клинический случай ангиосаркомы: дифференциально-диагностический путь. Клиническая дерматология и венерология. 2019;18(6):699-703. DOI: 10.17116/klinderma201918061699
Shchava S.N., Serdjukova E.A., Redkina N.A. et al. Clinical case of angiosarcoma: differential diagnostic pathway. Russian Journal of Clinical Dermatology and Venereology. 2019;18(6):699-703. DOI: 10.17116/klinderma201918061699 (in Russian).
15. Титов К.С., Джамилов Ш.Р., Лебединский И.Н. и др. Клинический случай диагностики и лечения рака кожи из сальных желез. Саркомы костей, мягких тканей и опухоли кожи. 2024;16(2):87-93. DOI: 10.17650/2219-4614-2024-16-2-87-93
Titov K.S., Dzhamilov Sh.R., Lebedinsky I.N. et al. Clinical Case of Diagnosis and Treatment of Skin Cancer from Sebaceous Glands. Bone and soft tissue sarcomas, tumors of the skin. 2024;16(2):87-93. DOI: 10.17650/2219-4614-2024-16-2-87-93 (in Russian).
16. Катина М.А., Лесничая О.В., Рязанова Н.В. Дерматофибросаркома выбухающая в дерматологической практике. Клинический случай. Consilium Medicum. 2022;24(8):523-8. DOI: 10.26442/20751753.2022. 8.201721
Katina M.A., Lesnichaya O.V., Ryazanova N.V. Dermatofibrosarcoma protuberans in dermatological practice. Case report. Consilium Medicum. 2022;24(8):523-8. DOI: 10.26442/20751753.2022.8.201721 (in Russian).
17. Garcovich S, Colloca G, Sollena P et al. Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. Aging Dis 2017;8(5):643-61. DOI: 10.14336/AD.2017.0503
18. Zheng DX, Cwalina TB, Mulligan KM et al. Prevalence and predictors of transportation barriers to health care among US adults with a history of skin cancer. J Am Acad Dermatol 2023;88(1):201-203. DOI: 10.1016/j.jaad.2022.04.023
19. Shelton ME, Adamson AS. Review and Update on Evidence-Based Surgical Treatment Recommendations for Nonmelanoma Skin Cancer. Dermatol Clin 2019;37(4):425-33. DOI: 10.1016/j.det.2019.05.002
20. Бройнингер X., Белова И.А. Микроскопически контролируемая хирургия с трехмерным гистологическим контролем, тумесцентная локальная анестезия и внутрикожная шовная техника под натяжением в лечении злокачественных новообразований кожи. Опухоли головы и шеи. 2018;8(3):21-36. DOI: 10.17650/2222-1468-2018-8-3-21-36
Breuninger H., Belova I.A. Microscopically controlled surgery with three-dimensional histology, tumescent local anesthesia and intracutaneous sutures for high tension in the treatment of skin cancer. Head and Neck Tumors (HNT). 2018;8(3):21-36. DOI: 10.17650/2222-1468-2018-8-3-21-36 (in Russian).
21. Brodland DG, Zitelli JA. Surgical margins for excision of primary cutaneous squamous cell carcinoma. J Am Acad Dermatol 1992;27(2 Pt 1):241-8. DOI: 10.1016/0190-9622(92)70178-i
22. Quazi SJ, Aslam N, Saleem H et al. Surgical Margin of Excision in Basal Cell Carcinoma: A Systematic Review of Literature. Cureus 2020;12(7):e9211. DOI: 10.7759/cureus.9211
23. Coady-Fariborzian L, Anstead C, Anna Paul S. Surgical Treatment of Nonmelanoma Skin Cancer in Older Adult Veterans. Fed Pract 2022;39(Suppl 3):S45-S49. DOI: 10.12788/fp.0283
24. Smeets NW, Krekels GA, Ostertag JU et al. Surgical excision vs Mohs‘ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004;364(9447):1766-72. DOI: 10.1016/S0140-6736(04)17399-6
25. Leibovitch I, Huilgol SC, Selva D et al. Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years. J Am Acad Dermatol 2005;53(2):253-60. DOI: 10.1016/j.jaad.2005.02.059
26. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26(6):976-90. DOI: 10.1016/0190-9622(92)70144-5
27. Ferry AM, Sarrami SM, Hollier PC et al. Treatment of Non-melanoma Skin Cancers in the Absence of Mohs Micrographic Surgery. Plast Reconstr Surg Glob Open 2020;8(12):e3300. DOI: 10.1097/GOX.0000000000003300
28. Mendez BM, Thornton JF. Current Basal and Squamous Cell Skin Cancer Management. Plast Reconstr Surg 2018;142(3):373e-387e. DOI: 10.1097/PRS.0000000000004696.
29. Tongdee E, Psomadakis CE, Paka P et al. Emerging noninvasive treatments of nonmelanoma skin cancers. Cutis 2020;105(3):138-42.
30. Renzi M Jr, Schimmel J, Decker A, Lawrence N. Management of Skin Cancer in the Elderly. Dermatol Clin 2019;37(3):279-86. DOI: 10.1016/j.det.2019.02.003
31. Neale H, Michelon M, Jacob S et al. Topical 5% 5-fluorouracil versus procedural modalities for squamous cell carcinoma in situ and superficial basal cell carcinoma: A retrospective cohort analysis. J Am Acad Dermatol 2022;87(2):423-5. DOI: 10.1016/j.jaad.2021.08.045
32. Alessi SS, Sanches JA, Oliveira WR et al. Treatment of cutaneous tumors with topical 5% imiquimod cream. Clinics (Sao Paulo) 2009;64(10):961-6. DOI: 10.1590/S1807-59322009001000005
33. Lanoue J, Goldenberg G. Basal Cell Carcinoma: A Comprehensive Review of Existing and Emerging Nonsurgical Therapies. J Clin Aesthet Dermatol 2016;9(5):26-36.
34. Casey D, Demko S, Shord S et al. FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma. Clin Cancer Res 2017;23(10):2377-81. DOI: 10.1158/1078-0432.CCR-16-2051
35. Раджабова З.А., Котов М.А., Бекяшева З.С. и др. Опыт применения ингибитора сигнального пути Hedgehog в лечении рецидивирующего местно-распространенного и метастатического базальноклеточного рака кожи. Опухоли головы и шеи. 2019;9(4):38-42. DOI: 10.17650/2222-1468-2019-9-4-38-42
Radzhabova Z.A., Kotov M.A., Bekyasheva Z.S. et al. Use of the Hedgehog signaling pathway inhibitor in the treatment of recurrent locally advanced and metastatic basal cell skin cancer. Head and Neck Tumors (HNT). 2019;9(4):38-42. DOI: 10.17650/2222-1468-2019-9-4-38-42 (in Russian).
36. Skvara H, Kalthoff F, Meingassner JG et al. Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol 2011;131(8):1735-44. DOI: 10.1038/jid.2011.48
37. Brancaccio G, Pea F, Moscarella E, Argenziano G. Sonidegib for the Treatment of Advanced Basal Cell Carcinoma. Front Oncol 2020;10:582866. DOI: 10.3389/fonc.2020.582866
38. Markham A, Duggan S. Cemiplimab: First Global Approval. Drugs 2018;78(17):1841-6. DOI: 10.1007/s40265-018-1012-5
39. Migden MR, Rischin D, Schmults CD et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med 2018;379(4):341-51. DOI: 10.1056/NEJMoa1805131
40. Bendell J, Andre V, Ho A et al. Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Naïve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res 2018;24(9):2082-91. DOI: 10.1158/1078-0432.CCR-17-0723
41. Lear JT, Corner C, Dziewulski P et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer 2014;111(8):1476-81. DOI: 10.1038/bjc.2014.270
42. Basset-Seguin N, Sharpe HJ, de Sauvage FJ. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma. Mol Cancer Ther 2015;14(3):633-41. DOI: 10.1158/1535-7163.MCT-14-0703
43. Mackey M, Shahsavari A, Mackey VT. Intralesional 5-Fluorouracil in the Treatment of Lower Leg Squamous Cell Carcinoma. J Drugs Dermatol 2018;17(11):1241-3.
44. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 2011;64(2):413-22. DOI: 10.1016/j.jaad.2009.12.013
45. Marka A, Rodgers D, Zelaya Castillo L et al. Dilute Intralesional 5-Fluorouracil for the Treatment of Squamous Cell Carcinomas and Keratoacanthomas: A Case Series. J Drugs Dermatol 2023;22(5):507-8. DOI: 10.36849/JDD.5058
46. Nestor MS, Berman B, Goldberg D et al. Consensus Guidelines on the Use of Superficial Radiation Therapy for Treating Nonmelanoma Skin Cancers and Keloids. J Clin Aesthet Dermatol 2019;12(2):12-8.
47. Benkhaled S, Van Gestel D, Gomes da Silveira Cauduro C et al. The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature. Front Med (Lausanne) 2022;9:913269. DOI: 10.3389/fmed.2022.913269
48. Gunaratne DA, Veness MJ. Efficacy of hypofractionated radiotherapy in patients with non-melanoma skin cancer: Results of a systematic review. J Med Imaging Radiat Oncol 2018;62(3):401-11. DOI: 10.1111/1754-9485.12718
49. Chicheł A, Chyrek AJ, Kluska A, Burchardt WM. Advanced non-melanoma skin cancer in elderly patients: When surgery says NO, interventional radiotherapy (brachytherapy) says YES. J Contemp Brachytherapy 2023;15(4):235-44. DOI: 10.5114/jcb.2023.130715
50. Conforti C, Corneli P, Harwood C, Zalaudek I. Evolving Role of Systemic Therapies in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019;31(11):759-68. DOI: 10.1016/j.clon.2019.08.011
51. Barker CA, Dufault S, Arron ST et al. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma. J Clin Oncol 2024;42(19):2327-35. DOI: 10.1200/JCO.23.01708
52. Pollom EL, Bui TT, Chang AL et al. Concurrent Vismodegib and Radiotherapy for Recurrent, Advanced Basal Cell Carcinoma. JAMA Dermatol 2015;151(9):998-1001. DOI: 10.1001/jamadermatol.2015.0326
53. Гешева Э.М., Печатникова Е.А., Потекаев Н.Н. и др. Лучевая диагностика и лучевая терапия в дерматоонкологии. Клиническая дерматология и венерология. 2021;20(5):74-82. DOI: 10.17116/klinderma20212005174
Gesheva E.M., Pechatnikova E.A., Potekaev N.N. et al. Radiation diagnostics and radiation therapy in dermato-oncology. Russian Journal of Clinical Dermatology and Venereology. 2021;20(5):74-82. DOI: 10.17116/klinderma20212005174 (in Russian).
54. Tran A, Moloney M, Kaczmarski P et al. Analysis of image-guided superficial radiation therapy (IGSRT) on the treatment of early-stage non-melanoma skin cancer (NMSC) in the outpatient dermatology setting. J Cancer Res Clin Oncol 2023;149(9):6283-91. DOI: 10.1007/s00432-023-04597-2
55. Markowitz O, Tongdee E, Levine A. Optimal cosmetic outcomes for basal cell carcinoma: a retrospective study of nonablative laser management. Cutis 2019 May;103(5):292-7.
56. Sharon E, Snast I, Lapidoth M et al. Laser Treatment for Non-Melanoma Skin Cancer: A Systematic Review and Meta-Analysis. Am J Clin Dermatol 2021;22(1):25-38. DOI: 10.1007/s40257-020-00562-8
57. Soleymani T, Abrouk M, Kelly KM. An Analysis of Laser Therapy for the Treatment of Nonmelanoma Skin Cancer. Dermatol Surg 2017;43(5):615-24. DOI: 10.1097/DSS.0000000000001048
58. Farberg AS, Marson JW, Soleymani T. Advances in Photodynamic Therapy for the Treatment of Actinic Keratosis and Nonmelanoma Skin Cancer: A Narrative Review. Dermatol Ther (Heidelb) 2023;13(3):689-716. DOI: 10.1007/s13555-023-00888-1
59. Herron ED, Snyder AM, Hull CM et al. Fragile hands: targeting nonmelanoma skin cancer on older hands using 595 nm pulsed dye laser. Lasers Med Sci 2024;39(1):101. DOI: 10.1007/s10103-024-04047-6
60. Chauhan R, Munger BN, Chu MW et al. Age at Diagnosis as a Relative Contraindication for Intervention in Facial Nonmelanoma Skin Cancer. JAMA Surg 2018;153(4):390-2. DOI: 10.1001/jamasurg.2017.5073
61. Delaney A, Shimizu I, Goldberg LH, MacFarlane DF. Life expectancy after Mohs micrographic surgery in patients aged 90 years and older. J Am Acad Dermatol 2013;68(2):296-300. DOI: 10.1016/j.jaad.2012.1 0.016
62. Linos E, Parvataneni R, Stuart SE et al. Treatment of nonfatal conditions at the end of life: nonmelanoma skin cancer. JAMA Intern Med 2013;173(11):1006-12. DOI: 10.1001/jamainternmed.2013.639
63. Rogers EM, Connolly KL, Nehal KS et al. Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. J Am Acad Dermatol 2018;78(6):1119-24. DOI: 10.1016/j.jaad. 2017.12.048
64. Yourman LC, Lee SJ, Schonberg MA et al. Prognostic indices for older adults: a systematic review. JAMA 2012;307(2):182-92. DOI: 10.1001/jama.2011.1966
65. Keeler E, Guralnik JM, Tian H et al. The impact of functional status on life expectancy in older persons. J Gerontol A Biol Sci Med Sci 2010;65(7):727-33. DOI: 10.1093/gerona/glq029
66. Hwang SS, Scott CB, Chang VT et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress. Cancer Invest 2004;22(5):678-87. DOI: 10.1081/cnv-200032911
67. Renzi MA Jr, Belcher M, Brod B et al. Assessment of Functionality in Elderly Patients When Determining Appropriate Treatment for Nonmelanoma Skin Cancers. Dermatol Surg 2020;46(3):319-26. DOI: 10.1097/DSS.0000000000002028
68. Alam M, Norman RA, Goldberg LH. Dermatologic surgery in geriatric patients: psychosocial considerations and perioperative decision-making. Dermatol Surg 2002;28(11):1043-50. DOI: 10.1046/j.1524-4725.2002.02102.x
69. Wernli KJ, Henrikson NB, Morrison CC et al. Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016;316(4):436-47. DOI: 10.1001/jama.2016.5415
70. Federman DG, Kravetz JD, Kirsner RS. Skin cancer screening by dermatologists: prevalence and barriers. J Am Acad Dermatol 2002;46(5):710-4. DOI: 10.1067/mjd.2002.120531
71. US Preventive Services Task Force; Mangione CM, Barry MJ et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2023;329(15):1290-5. DOI: 10.1001/jama.2023.4342
72. Omara S, Wen D, Ng B et al. Identification of Incidental Skin Cancers Among Adults Referred to Dermatologists for Suspicious Skin Lesions. JAMA Netw Open 2020;3(12):e2030107. DOI: 10.1001/jamanetworkopen.2020.30107
73. Schoenborn NL, Massare J, Park R et al. Assessment of Clinician Decision-making on Cancer Screening Cessation in Older Adults With Limited Life Expectancy. JAMA Netw Open 2020;3(6):e206772. DOI: 10.1001/jamanetworkopen.2020.6772
74. Sima CS, Panageas KS, Schrag D. Cancer screening among patients with advanced cancer. JAMA 2010;304(14):1584-91. DOI: 10.1001/jama.2010.1449
75. Mainville L, Smilga AS, Fortin PR. Effect of Nicotinamide in Skin Cancer and Actinic Keratoses Chemoprophylaxis, and Adverse Effects Related to Nicotinamide: A Systematic Review and Meta-Analysis. J Cutan Med Surg 2022;26(3):297-308. DOI: 10.1177/12034754221078201
76. Haisma MS, Greven N, Logendran M et al. Chronic Use of Hydrochlorothiazide and Risk of Skin Cancer in Caucasian Adults: A PharmLines Initiative Inception Cohort Study. Acta Derm Venereol 2023;103:adv3933. DOI: 10.2340/actadv.v103.3933
77. Polesie S, Gillstedt M, Schmidt SAJ et al. Use of methotrexate and risk of skin cancer: a nationwide case-control study. Br J Cancer 2023;128(7):1311-9. DOI: 10.1038/s41416-023-02172-7
78. Peters MG. Long-Term Use of Azathioprine in the Management of Autoimmune Hepatitis. Gastroenterol Hepatol (NY) 2019;15(5):277-9.
For citation:Pirozhnikova A.A., Stetsyuk M.V., Kudrevich K.A., Abdurakhmanova E.E., Umerova A.I., Tamasyan E.G., Kovali D.Yu., Tovmasyan K.A., Filipova V.A., Diarova A.A., Nemirova O.V., Bagdasaryan A.A., Shadiev Kh.-A.A. The current state of the issue of diagnosis and treatment of non-melanoma skin cancer in elderly patients. Clinical review for general practice. 2024; 5 (12): 56–66 (In Russ.). DOI: 10.47407/kr2024.5.12.00538
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
